Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium
Publication year
2021Source
Cts-Clinical and Translational Science, 14, 1, (2021), pp. 29-35ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Pharmacology-Toxicology
Intensive Care
Journal title
Cts-Clinical and Translational Science
Volume
vol. 14
Issue
iss. 1
Page start
p. 29
Page end
p. 35
Subject
Radboudumc 11: Renal disorders RIHS: Radboud Institute for Health Sciences; Intensive Care - Radboud University Medical Center; Pharmacology-Toxicology - Radboud University Medical CenterAbstract
On April 24, 2019, a symposium on Pediatric Pharmacokinetics and Dose Predictions was held as a satellite meeting to the 10th Juvenile Toxicity Symposium. This symposium brought together scientists from academia, industry, and clinical research organizations with the aim to update each other on the current knowledge on pediatric drug development. Through more knowledge on specific ontogeny profiles of drug metabolism and transporter proteins, integrated into physiologically-based pharmacokinetic (PBPK) models, we have gained a more integrated understanding of age-related differences in pharmacokinetics (PKs), Relevant examples were presented during the meeting. PBPK may be considered the gold standard for pediatric PK prediction, but still it is important to know that simpler methods, such as allometry, allometry combined with maturation function, functions based on the elimination pathway, or linear models, also perform well, depending on the age range or the mechanisms involved. Knowledge from different methods and information sources should be combined (e.g., microdosing can reveal early read-out of age-related differences in exposure), and such results can be a value to verify models. To further establish best practices for dose setting in pediatrics, more in vitro and in vivo research is needed on aspects such as age-related changes in the exposure-response relationship and the impact of disease on PK. New information coupled with the refining of model-based drug development approaches will allow faster targeting of intended age groups and allow more efficient design of pediatric clinical trials.
This item appears in the following Collection(s)
- Academic publications [246936]
- Electronic publications [134293]
- Faculty of Medical Sciences [93487]
- Open Access publications [107816]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.